Alvotech Receives FDA Acceptance for Review of Entyvio Biosimilar AVT80

Alvotech announced that the FDA has accepted its Biologics License Application for AVT80, a proposed subcutaneous biosimilar of Merck's Entyvio, expanding its biosimilar development pipeline.

31 Aug, 08:30 — 31 Aug, 08:30

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual3d ago

Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations - Taiwan News

Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations Taiwan News

Read full article →

Alvotech Receives FDA Acceptance for Review of Entyvio Biosimilar AVT80

Sources

Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations - Taiwan News

Related Stories

DSS Inc. Launches Public Offering to Raise Capital

Trump Administration Pushes Washington Arch Project and Mail Voting Rules

US Investigates Deadly Strike on Iranian Wedding Linked to American Munitions

South Korea Evaluates Potential Military Deployment to Strait of Hormuz